Strata Critical Medical (SRTA) Cash & Current Investments (2019 - 2026)

Strata Critical Medical has disclosed Cash & Current Investments across 8 years of filings, most recently posting $58.8 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 51.01% year-over-year to $58.8 million; the TTM figure through Mar 2026 stood at $58.8 million (down 51.01% YoY), while the FY2025 annual figure was $61.2 million, down 50.95% from the prior year.
• Cash & Current Investments fell to $58.8 million in Q1 2026, from $61.2 million in the prior quarter.
• Over the last five years, Cash & Current Investments for SRTA reached as high as $269.1 million in Q1 2022 and fell as low as $53.4 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $142.0 million (2024), against an average of $147.1 million.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 3482.16% — and 2025, when it sank 60.81%.
• A 5-year view of Cash & Current Investments shows it stood at $153.8 million in 2022, then fell by 9.37% to $139.4 million in 2023, then fell by 10.46% to $124.8 million in 2024, then sank by 50.95% to $61.2 million in 2025, then declined by 3.99% to $58.8 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $58.8 million, $61.2 million, and $53.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.